Esperion Therapeutics Newsroom

Goldman Sachs Upgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Raises Target Price to $4

Moomoo NewsDec 18 01:31 ET

Cantor Fitzgerald Initiates Esperion Therapeutics(ESPR.US) With Buy Rating, Announces Target Price $8

Moomoo NewsDec 17 17:31 ET

Esperion Therapeutics Analyst Ratings

BenzingaDec 17 08:41 ET

Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target

MT NewswiresDec 17 07:37 ET

Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsDec 13 13:31 ET

Esperion Therapeutics Price Target Maintained With a $6.00/Share by Needham

Dow JonesDec 13 12:44 ET

Esperion Therapeutics Analyst Ratings

BenzingaDec 12 12:19 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsDec 12 10:31 ET

Jefferies Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsDec 11 11:32 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsDec 2 10:32 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsNov 26 10:32 ET

Esperion Therapeutics Analyst Ratings

BenzingaNov 19 06:39 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsNov 19 06:31 ET

A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $2.05 to $16

Moomoo NewsNov 8 08:14 ET

Esperion Therapeutics Analyst Ratings

BenzingaNov 8 05:15 ET

BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating

Moomoo NewsOct 28 10:31 ET

Esperion Therapeutics Analyst Ratings

BenzingaOct 2 10:48 ET

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsOct 2 10:33 ET

JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsSep 3 11:32 ET

Esperion Therapeutics Analyst Ratings

BenzingaAug 12 13:55 ET